REFERENCES:

1. Agarwal R., Katare O.P., Vyas S.P., (2001), Preparation and in-vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol, *International Journal of Pharm*, **228**, 43-52.

2. Agarwal R., Saraswat A., Kaur I., Katare O.P., Kumar B., (2002). A novel liposomal formulation of dithranol for psoriasis: Preliminary results, *Journal of Dermatology*, **29**, 529-532.

3. Agarwal Y., Petkar K. C. and Sawant K. K. (2010), Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. *International journal of pharmaceutics*, **30, (1-2),** 93-102.

4. Baboota S., Alam S., Sharma S., Sahni J. K., Kumar A. and Ali J., (2011), Nanocarrier-based hydrogel of betamethasone dipropionate and salicylic acid for treatment of psoriasis, *International Journal of Pharm Investigation*, **1 (3)**, 139–147.

5. Brune A, Lin M. P, Russi D. C and Paller A. S., (2007), Tacrolimus Ointment is Effective for Psoriasison the Face and Intertriginous Areas in Pediatric Patients, *Pharmacology and Therapeutics Pediatric Dermatology*, **24 (1)** , 76–80.

6. Chmielewska, L. Konieczna, and H. Lamparczyk, (2006) Development of a reversed-phase hplc method for analysis of fluocinolone acetonide in gel and ointment. *Acta Chromatographica*, **16**, 80-91.

7. Crow J. M., (2012), Therapeutics: Silencing Psoriasis, *Nature*, **492**, S58- S59.

8. Gidwani S. K. and Singnurkar P. S. (2003), Composition for delivery of dithranol. *India: European Patent Office*, 1-14.

9. Guenther L C (2009), Treatments for scalp psoriasis with emphasis on Calcitriol plus Betamethasone Dipropionate gel (xamiol), *Skin Therapy Letter*, **14 (4).**

10. Gupta A K. and Chow M. (2004), A review of Prednicarbate (Dermatop), *Skin Therapy Letter*, **9 (10)**: 5-6, 9.

11. Johnston S. E, Gill N. L., Wei Y, Markovich R, and Rustum A. M (2010). Development and Validation of a Stability-Indicating RP-HPLC Method for Simultaneous Assay of Betamethasone Dipropionate, Chlorocresol, and for the Estimation of Betamethasone Dipropionate Related Compounds in a Pharmaceutical Cream and Ointment. *Journal of Chromatographic Science*, **(48),** 733 -741.

12. Katare O P, Kumar R, Bhoop B S, Dogra S and Kaur I (2009). Microemulsion organogel system for site-specific delivery of cyclosporine. Kolkata (India): *The Patent Office Journal*, 6211.

13. Katare O. P., Kaisav R., Singh B and Dogra S. (2010) Novel Drug Delivery systems in topical treatment of psoriasis- Rigors and Trigors, *Indian journal of Dermatology, venereology and leprology*, **76 (6)**: 612 – 621.

14. Katare O. P., Kumar R., Bhoop B. S., Dogra S, Kaur I (2009), A multicompartmental liposomal system for topical drug delivery. Kolkata (India): *The Patent Office Journal*, 6210.

15. Kim S T, Jang D J, Kim J H, Park J Y, Lim J S, Lee S Y (2009) Topical administration of cyclosporin A in a solid lipid nanoparticle formulation. *Pharmazie*, **64**, 510-514.

16. Krueger J. G and Bowcock A. (2005), Psoriasis Pathophysiology: Current Concepts of pathogenesis. *Annual Rheumatoid Diseases*, **64 (2)**, 30 – 36.

17. Kurian A. and Barankin B., (2011), Current effective topical therapies in the management of Psoriasis, *Skin Therapy Letter*, **16 (1)**, 4 – 7.

18. Lin Y K, Huang Z R, Zhuo R Z and Fang J Y (2010), Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. *International Journal of Nanomedicine*, **5**, 117-128.

19. Mansouri P and Farshi S (2006) , Pimecrolimus 1 percent cream in the treatment of psoriasis in a child, *Dermatology online journal*, **12 (2)**:7

20. Marwaha T. K., (2013), Formulation Development of anti-psoriatic topical babchi oil emulgel, Research and Reviews: Journal of Herbal Sciences; **2 (2).**

21. Mei Z, Chen H, Weng T, Yang Y and Yang X (2003) ,Solid lipid nanoparticle and microemulsion for topical delivery of triptolide, *European Journal of Pharmaceutics and Biopharmaceutics*, **(56)** , 189 - 196.

22. Mishra A and Kalariya M. (2004), Methotrexate-Loaded Solid Lipid Nanoparticles for Topical Treatment of Psoriasis: Formulation & Clinical Implications, *Drug Development and Delivery*, **4 (8).**

23. Molin S, Abeck D, Guilbert A and Bellosta M (2013), Mometasone Furoate : A well established topical corticosteroid now with improved galenic formulation, *Clinical and Experimental Dermatology Research*, **4 (3).**

24. Mrowietz U, Wustlich S, Hoexter G, Graeber M, Brautigam M and Luger T (02/2003), An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion, *Acta Dermato Venereologica*, **83(5)**, 351-353.

25. Nestle F O, Kaplan D H and Barker J (2009), Mechanism of Disease Psoriasis. *The New England Journal of Medicine*, **361 (5),** 496 – 509.

26. OECD Guideline for the testing of chemicals: www.oecd.org. (2012)

27. Pasupathi A, Palanisamy P, Jaykar B, Chandira R M. and Venkateshwarlu B. S. (2012). Formulation, Development, Evaluation of Calcipotriol and Clobetasol Propionate Ointment, *Indian Journal of Pharmacy and Biotechnology*, **1 (1).**

28. Pavliv L., Freeburn N, Wilke T, Chin-chin C, Shetty B. and Tyle P. , (1994),Topical formulation development of a novel thymidylate synthase inhibitor for the treatment of psoriasis. *International journal of pharmaceutics*, **105 (3)**, 227- 233.

29. Psoriasis by Mayo Clinic (2012), www.mayoclinic.com/health/psoriasis.

30. Psoriasis Pathophysiology (2012), Practicing clinicians.com. www. Practicingclinicians.com/eclinic/psoriasis.

31. Psoriasis Treatment (2012), University of Maryland Medical Center (UMMC) www.unm.edu.

32. Psoriasis Treatment: National Psoriasis Foundation-USA (2012). www.psoriasis.org.

33. Roy C., Chakrabarty J., and Ratti R R., (2013). Development and validation of a stability-indicating NP-HPLC method forsimultaneous determination of betamethasone dipropionate and calcipotrienein topical dosage form. *Archives of Applied Science Research*, **5 (2) ,** 15-24

34. S. Racheva, R. Bachvarova, J and Dimitrova (2008), Treatment of psoriasis vulgaris with elidel. *Journal of IMAB - Annual Proceeding (Scientific Papers)*, book 1

35. Saraswat A, Agarwal R, Katare OP, Kaur I, Kumar B. (2007), A randomized, double-blind, vehicle-controlled study of a novel liposomal dithranol formulation in psoriasis, *Journal of Dermatological Treatment*, **(18) ,** 40-45.

36. Saraswat A, Agarwal R, Kaur I, Katare OP, Kumar B (2002), Fabric-staining properties and washability of a novel liposomal dithranol formulation, *Journal of Dermatological Treatment*, **(13)** , 119 -122.

37. Scheinfeld N (2004) ,The use of topical tacrolimus and pimecrolimus to treat psoriasis: A review, *Dermatology Online Journal*, **10 (1)**: 3

38. Shah K. A., Date K.A., Joshi M. D., and Patravale V. B., (2007), Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery, *International Journal of Pharmaceutics*,**10; 345(1-2),** 163-171.

39. Singh M., Charde M, Shukla R and Charde R. M., (2011), Determination of Calcipotriene in Calcipotriene Cream 0.05% w/w by RP-HPLC method development and validation. *Research Journal of Pharmacy and Technology*, **4 (8)**, 1219 – 1223.

40. Trotta M, Pattarino F and Gasco M R (1996), Influence of counter ions on the skin permeation of methotrexate from water--oil microemulsions, *Pharmaceutica Acta Helvetiae,* **(71),** 135- 140.

41. Verma D D and Fahr A (2004). Synergistic penetration enhancement effect of ethanol and phospholipids on the topical delivery of cyclosporin A, *Journal of Control Release;* **(97)**, 55-66.

42. Wheeler et al, United States Patent: Pub. No: US2008/0234239A1

43. Zonneveld I. M., Rubins A., Jablonska S., Dobozy A., Ruzicka T., Kind T., Dubertret L., Bos J. D and Ground C.K., (1998), Topical tacrolimus is not effective in chronic plaque psoriasis, *Archieves of Dermatology*, **134 (9)** , 1101-1102.